In which case it doesnt matter whether we increase dystrophin or not, we still achieve better results, in a mouse study, in combo with exon skipping.
I agree it does seem strange that results were "INSUFFICIENTLY SENSITIVE" ....what does that mean, and how could they not foresee such an outcome.
To continue down the rabbit hole... Sarepta can kick the can down the road with the fda (remember fda can now relinquish approvals) until our tox study is complete, or well underway to then swap over to ATL1102 when we have rights to monetise our drug. If we were to give advocates a sniff of another option (unapproved ANP) sarepta may lose valuable revenue, on marketing hold, waiting for us to jump the monkey hurdle. Because you wouldnt get behind a drug if there was something better just around the corner.
- Forums
- ASX - By Stock
- PER
- Ann: PIIb DMD trial approved in Bulgaria- UK, Australia advancing
Ann: PIIb DMD trial approved in Bulgaria- UK, Australia advancing, page-30
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.0¢ |
Change
-0.001(1.23%) |
Mkt cap ! $72.12M |
Open | High | Low | Value | Volume |
8.2¢ | 8.2¢ | 8.0¢ | $63.52K | 777.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 43377 | 8.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.2¢ | 97561 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 43377 | 0.080 |
2 | 212658 | 0.078 |
1 | 200000 | 0.077 |
3 | 91500 | 0.076 |
4 | 206988 | 0.075 |
Price($) | Vol. | No. |
---|---|---|
0.082 | 97561 | 1 |
0.083 | 214000 | 1 |
0.084 | 67142 | 2 |
0.085 | 141000 | 2 |
0.086 | 106100 | 2 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |